Eric Rose Buys 30,310 Shares of Mesoblast Limited (ASX:MSB) Stock

Mesoblast Limited (ASX:MSB) insider Eric Rose acquired 30,310 shares of the stock in a transaction on Thursday, January 16th. The shares were purchased at an average price of A$16.70 ($10.44) per share, for a total transaction of A$506,207.31 ($316,379.57).

Mesoblast Price Performance

The company has a quick ratio of 1.82, a current ratio of 1.18 and a debt-to-equity ratio of 24.76.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.